Home/ Stocks/ BCAX

Bicara Therapeutics Inc. Common Stock

BCAX XNAS

$28.06 +0.55 (+2.00%) ▲ 15-min delayed

Open

$27.90

High

$28.43

Low

$26.90

Volume

570.6K

Market Cap

$1.81B

About Bicara Therapeutics Inc. Common Stock

Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b. The company's goal is to build a fully integrated, commercial-stage biopharmaceutical company that develops important therapies for people living with cancer, starting with ficerafusp alfa.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 103 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$0	$-56,211,000	$-0.93
FY 2025	$0	$-137,950,000	$-2.52
Q3 2025	$0	$-36,330,000	$-0.67
Q2 2025	$0	$-27,388,000	$-0.50

Related Market News

No specific coverage for BCAX yet. Check out our latest market news or earnings calendar.

Get BCAX Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Bicara Therapeutics Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.